Kopran Analyst Review May 2026

This Kopran analyst review for May 2026 covers the key data investors need for KOPRAN at its current price of Rs 248. Kopran (NSE: KOPRAN) is a pharmaceutical company with a market capitalisation of approximately Rs 900 crore, manufacturing APIs and formulations for domestic and regulated export markets. The analyst consensus target of Rs 315 implies meaningful upside, and this Kopran analyst review examines technical levels, business performance, valuation, and key risks for KOPRAN through FY27.

Click Here – Get Free Investment Predictions

Kopran Company Snapshot May 2026

Kopran produces macro-lide antibiotics (clarithromycin, azithromycin), APIs, and formulations with WHO GMP approved facilities. Exports to Europe, US, and Australia contribute significant revenue. The table below summarises the key data referenced in this Kopran analyst review.

Parameter	Value
NSE Ticker	KOPRAN
Sector	Pharmaceuticals – APIs and Formulations
CMP (May 2026)	Rs 248
52 Week High	Rs 385
52 Week Low	Rs 198
Market Cap	Rs 900 Crore
Trailing P/E	18x
Analyst Consensus Target	Rs 315
Bull Case Target	Rs 390
Bear Case Target	Rs 218

Analyst Insight in This Kopran Analyst Review

Senior Research Analyst Ankit Jaiswal flags Kopran as a stock to watch in May 2026. At Rs 248, Ankit Jaiswal identifies key support in the Rs 201.96 to Rs 235.60 band and resistance near Rs 262.88. He suggests watching Kopran for a potential move toward Rs 315, subject to Pharmaceuticals – APIs and Formulations sector momentum. Ankit Jaiswal’s view is one input in this Kopran analyst review and does not constitute a trade recommendation.

Technical Analysis in This Kopran Analyst Review

At Rs 248, KOPRAN is trading within its 52-week band of Rs 198 to Rs 385. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 201.96 to Rs 235.60 band while resistance is seen in the Rs 262.88 to Rs 281.50 zone. A sustained move above Rs 262.88 could open the path toward the analyst consensus target of Rs 315 as identified in this Kopran analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 201.96 to Rs 235.60 – investors tracking this Kopran analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for KOPRAN.
• Resistance Zone: Rs 262.88 to Rs 281.50 – a sustained close above Rs 262.88 would be a positive breakout signal worth flagging in this Kopran analyst review.
• Medium-Term Target: The analyst consensus of Rs 315 represents the base-case upside scenario in this Kopran analyst review.

Business Segment Analysis

Macrolide Antibiotic APIs (Clarithromycin, Azithromycin)

This is the primary revenue and margin driver for Kopran, directly supporting the earnings trajectory toward the consensus target of Rs 315.

Formulations (Tablets, Capsules, Liquid)

This segment adds scale and diversification to Kopran’s business model and is a meaningful EPS contributor through FY27 and FY28.

Regulated Market Export (US, Europe, Australia)

This represents the medium-term growth frontier for Kopran and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Kopran Analyst Review

At Rs 248, Kopran trades at a trailing P/E of 18x. This Kopran analyst review presents three scenarios: a bull case of Rs 390 on strong earnings delivery, a base case of Rs 315 at analyst consensus, and a bear case of Rs 218 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Kopran analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 390	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 315	Moderate growth, analyst consensus estimate
Bear Case	Rs 218	Earnings miss or macro headwinds

Trade Outlook for Kopran

Based on the technical and fundamental analysis in this Kopran analyst review, investors might watch KOPRAN near the support zone of Rs 201.96 to Rs 235.60 for potential opportunities. A flag above Rs 262.88 could suggest improving momentum toward Rs 315. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Kopran in FY27

A well-rounded Kopran analyst review must assess downside risks. Key risks for Kopran include a macro slowdown affecting Pharmaceuticals – APIs and Formulations sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in KOPRAN.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Kopran Analyst Review Verdict for 2026

This Kopran analyst review concludes that at Rs 248, KOPRAN offers a defined risk-reward with a consensus target of Rs 315. The 52-week range of Rs 198 to Rs 385 provides context on the current entry point. Use this Kopran analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on KOPRAN.

Frequently Asked Questions: Kopran Analyst Review 2026

What is the analyst target for Kopran in 2026?

The analyst consensus target is Rs 315, with a bull case of Rs 390 and a bear case of Rs 218. This Kopran analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Kopran a good investment at Rs 248?

At Rs 248 with a P/E of 18x and a consensus target of Rs 315, this Kopran analyst review is constructive for medium to long-term investors in the Pharmaceuticals – APIs and Formulations sector. Always consult a SEBI-registered advisor before investing.

What is Kopran’s 52-week high and low?

The 52-week high is Rs 385 and the 52-week low is Rs 198. At Rs 248, KOPRAN is positioned within this range as noted in this Kopran analyst review.

What are the key risks for Kopran?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – APIs and Formulations sector as assessed in this Kopran analyst review.

Where can I track live data for Kopran?

Track Kopran’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Kopran analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.